Metropolitan Life Insurance CO Mersana Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

36 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.16 - $5.94 $6,737 - $18,526	3,119 Added 200.19%	4,677 $20,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $2.34 $3,938 - $8,302	-3,548 Reduced 69.49%	1,558 $3,000
Q2 2023 Aug 10, 2023	BUY	$3.08 - $9.55 $3,763 - $11,670	1,222 Added 31.46%	5,106 $16,000
Q1 2023 May 15, 2023	SELL	$4.0 - $7.02 $10,496 - $18,420	-2,624 Reduced 40.32%	3,884 $15,000
Q4 2022 Jun 14, 2023	BUY	$5.65 - $7.86 $14,825 - $20,624	2,624 Added 67.56%	6,508 $38.1 Million
Q4 2022 Mar 30, 2023	BUY	$5.65 - $7.86 $9,887 - $13,755	1,750 Added 36.78%	6,508 $38,000
Q4 2022 Feb 15, 2023	BUY	$5.65 - $7.86 $9,887 - $13,755	1,750 Added 36.78%	6,508 $38,000
Q3 2022 Jun 14, 2023	BUY	$4.63 - $8.0 $4,046 - $6,992	874 Added 22.5%	4,758 $32.2 Million
Q2 2022 Jun 20, 2023	BUY	$2.84 - $5.0 $2,482 - $4,370	874 Added 22.5%	4,758 $21,000
Q1 2022 Jun 20, 2023	BUY	$3.74 - $6.63 $3,268 - $5,794	874 Added 22.5%	4,758 $18,000
Q1 2022 Mar 30, 2023	SELL	$3.74 - $6.63 $17,817 - $31,585	-4,764 Reduced 50.03%	4,758 $18,000
Q1 2022 May 12, 2022	SELL	$3.74 - $6.63 $17,817 - $31,585	-4,764 Reduced 50.03%	4,758 $19,000
Q4 2021 Jun 21, 2023	BUY	$5.48 - $9.86 $30,896 - $55,590	5,638 Added 145.16%	9,522 $59,000
Q4 2021 Mar 30, 2023	SELL	$5.48 - $9.86 $29,756 - $53,539	-5,430 Reduced 36.32%	9,522 $59,000
Q4 2021 Feb 15, 2022	SELL	$5.48 - $9.86 $29,756 - $53,539	-5,430 Reduced 36.32%	9,522 $59,000
Q3 2021 Jun 21, 2023	BUY	$8.56 - $14.47 $94,742 - $160,153	11,068 Added 284.96%	14,952 $140,000
Q3 2021 Mar 30, 2023	SELL	$8.56 - $14.47 $41,259 - $69,745	-4,820 Reduced 24.38%	14,952 $140,000
Q3 2021 Nov 15, 2021	SELL	$8.56 - $14.47 $41,259 - $69,745	-4,820 Reduced 24.38%	14,952 $141,000
Q2 2021 Jun 21, 2023	BUY	$13.28 - $18.07 $210,992 - $287,096	15,888 Added 409.06%	19,772 $268,000
Q2 2021 Mar 30, 2023	BUY	$13.28 - $18.07 $68,617 - $93,367	5,167 Added 35.38%	19,772 $268,000
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $262,372 - $357,008	19,757 Added 131713.33%	19,772 $269,000
Q1 2021 Jun 26, 2023	BUY	$15.31 - $26.52 $164,138 - $284,320	10,721 Added 276.03%	14,605 $236 Million
Q1 2021 Mar 30, 2023	SELL	$15.31 - $26.52 $18,815 - $32,593	-1,229 Reduced 7.76%	14,605 $236,000
Q1 2021 May 14, 2021	SELL	$15.31 - $26.52 $242,188 - $419,519	-15,819 Reduced 99.91%	15 $236,000
Q4 2020 Jun 22, 2023	BUY	$16.84 - $27.59 $201,238 - $329,700	11,950 Added 307.67%	15,834 $421,000
Q4 2020 Mar 30, 2023	BUY	$16.84 - $27.59 $5,860 - $9,601	348 Added 2.25%	15,834 $421,000
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $5,860 - $9,601	348 Added 2.25%	15,834 $421,000
Q3 2020 Jun 26, 2023	BUY	$16.2 - $25.7 $187,952 - $298,171	11,602 Added 298.71%	15,486 $288,000
Q3 2020 Mar 30, 2023	BUY	$16.2 - $25.7 $18,419 - $29,220	1,137 Added 7.92%	15,486 $288,000
Q3 2020 Nov 13, 2020	BUY	$16.2 - $25.7 $18,419 - $29,220	1,137 Added 7.92%	15,486 $288,000
Q2 2020 Jun 26, 2023	BUY	$5.24 - $23.4 $54,836 - $244,880	10,465 Added 269.44%	14,349 $335,000
Q2 2020 Mar 30, 2023	BUY	$5.24 - $23.4 $47,987 - $214,297	9,158 Added 176.42%	14,349 $335,000
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $47,987 - $214,297	9,158 Added 176.42%	14,349 $336,000
Q1 2020 Jul 12, 2023	BUY	$4.41 - $9.28 $5,763 - $12,128	1,307 Added 33.65%	5,191 $30,000
Q1 2020 Mar 30, 2023	SELL	$4.41 - $9.28 $5,807 - $12,221	-1,317 Reduced 20.24%	5,191 $30,000
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $22,892 - $48,172	5,191 New	5,191 $30,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $216M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account